Purchase this article with an account.
Ehtesham Shamsher, Ben Davis, Preeti Dev, Ljuban Grgic, Satyanarayana Somavarapu, Li Guo, M Francesca Cordeiro; Resveratrol nanoparticles are neuroprotective in vitro suggesting a potential to cure glaucoma and Alzheimer’s disease. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2494.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Resveratrol is a natural polyphenol found in red wine and dark chocolate with potential neuroprotective effects, which could treat glaucoma and Alzheimer’s disease. However, its hydrophobicity results in a low bioavailability limiting its clinical use. To date, many groups have attempted to formulate resveratrol with limited success.
In this study, we describe the development of a new nanoparticle formulation of resveratrol that allows solubility of more than 10 mg/ml of resveratrol and is stable over 90 days when stored at room temperature. The characterisation of these nanoparticles was achieved using spectrophotometry and dynamic light scattering demonstrating no aggregation and a particle diameter lower than 22 nm.
Resveratrol nanoparticles are well tolerated and protect R28 cells in vitro against cobalt chloride induced hypoxia with an IC50 (±SEM) of 938.5±127.0 µM versus 284.4 ± 35.6 µM for control group (p<0.001), glutamate induced excitoxicity with an IC50 (±SEM) of 29.32±3.00 mM versus 5.94±1.99 mM for control group (p<0.0001) and DL-homocysteine induced toxicity with an IC50 (±SEM) of 3.10±0.36 mM versus 2.05±0.06 mM for control group (p<0.05) by increasing significantly their viability in a dose-dependent manner.
These results show that a newly formulated resveratrol nanoparticle formulation is neuroprotective against insults known to mimic cellular stress of glaucoma and Alzheimer’s disease suggesting that it could be used to treat them. However, in vivo studies are needed to prove its efficacy further.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only